Soligenix Wins EU Orphan Drug Status for Behcet's Disease Therapy

Soligenix, a late-stage biopharmaceutical company trading on the NASDAQ under the ticker SNGX, has achieved a significant regulatory milestone with the European Commission granting orphan drug designation to its drug candidate dusquetide (SGX945) for the treatment of Behcet's Disease. This decision follows a positive recommendation from the European Medicines Agency and is supported by promising Phase 2a clinical data demonstrating the drug's biological efficacy and safety profile. The orphan designation is a crucial step forward, providing Soligenix with up to 10 years of market exclusivity in the European Union upon approval, which strengthens the company's commercial prospects for this rare disease therapy. This European recognition builds upon existing regulatory support from the U.S. Food and Drug Administration, which had previously granted both orphan drug and fast track designations for the same indication, highlighting the global potential of dusquetide.

The company's development pipeline is centered on its innovative innate defense regulator (IDR) platform technology, which targets significant unmet medical needs in rare autoimmune and inflammatory conditions. Beyond dusquetide for Behcet's Disease, Soligenix is advancing SGX942, another IDR candidate, for the treatment of oral mucositis in head and neck cancer patients. The company's broader portfolio is divided into two key business segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment also includes HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma that has completed a second Phase 3 study and is moving toward potential global commercialization, as well as SGX302 for psoriasis. The Public Health Solutions segment focuses on vaccine development, featuring candidates like RiVax® for ricin toxin, vaccines for filoviruses such as Marburg and Ebola, and CiVax™ for COVID-19, utilizing the proprietary ThermoVax® heat stabilization platform supported by government funding from agencies including the National Institute of Allergy and Infectious Diseases (NIAID).

This regulatory progress for dusquetide underscores Soligenix's strategic focus on rare diseases with limited treatment options, positioning the company as a key player in the biopharmaceutical landscape. The orphan drug designation not only accelerates the development pathway by offering regulatory and financial incentives but also validates the therapeutic potential of the IDR platform. Investors and stakeholders can access the full press release and the latest company updates through the InvestorBrandNetwork website, which provides comprehensive coverage and disclaimers for all published content. As Soligenix continues to advance its diverse pipeline, this milestone represents a pivotal moment in bringing novel treatments to patients suffering from debilitating conditions like Behcet's Disease, while also enhancing the company's value proposition in the competitive biotech market.